Stoke Therapeutics, Inc. STOK Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -577.5%-597pp | -11.2%+266pp | 13.2%+714pp | 20.2%+776pp | 20%+1,530pp | |
| Net margin | -529.2%-556pp | -3.7%+240pp | 19.7%+650pp | 26.3%+710pp | 26.3%+1,410pp | |
| EBITDA margin | -572.1%-593pp | -10.2%+261pp | 14.1%+701pp | 21.1%+761pp | 21.1%+1,500pp | |
| Returns | ||||||
| Return on equity | -45.6%-66.1pp | -2.4%+43.4pp | 15%+67.1pp | 18.2%+66.0pp | 20.5%+81.8pp | |
| Return on assets | -39.9%-56.4pp | -2%+33.6pp | 12.4%+52.0pp | 15.2%+51.8pp | 16.4%+61.0pp | |
| Return on invested capital | -114.4%— | -10.9%— | 17.3%— | 27.4%+429pp | —— | |
| Efficiency | ||||||
| Asset turnover | 0.1×-0.5× | 0.5×+0.4× | 0.6×+0.6× | 0.6×+0.5× | 0.6×+0.6× | |
| Liquidity | ||||||
| Current ratio | 9×+0.6× | 5.3×-0.5× | 6.5×+1.4× | 7×+0.3× | 8.4×+3.0× | |
| Quick ratio | 9×+0.6× | 5.3×-0.5× | 6.5×+1.4× | 7×+0.3× | 8.4×+3.0× | |
| Cash ratio | 3.8×-2.3× | 1.5×-1.7× | 2×-1.0× | 2.6×-1.7× | 6.2×+1.1× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Interest coverage | -13×-15.9× | -1.5×+6.5× | 2.1×+11.6× | 3.1×+13.1× | 2.9×+14.5× | |
| Per Share | ||||||
| Book value per share | $6.26+6.2% | $5.95+40.4% | $5.26+27.6% | $5.74+31.9% | $5.89+94.2% | |
| Valuation | ||||||
| Market capitalization | $1.93B+436% | $1.81B+210% | $1.29B+87.9% | $628.41M+0.6% | $359.62M-42.4% | |
| Enterprise value | $1.77B+1,855% | $1.73B+276% | $1.21B+123% | $532.22M+21.7% | $90.75M-79.9% | |
| Price / sales | 60×+58.2× | 9.8×-6.2× | 6.3×-34.7× | 3.1×-38.1× | 1.9×-77.7× | |
| Price / book | 4.9×+3.8× | 5.1×+2.6× | 4.2×+1.2× | 1.9×-0.7× | 1×-3.4× | |
| EV / sales | 55.3×+54.8× | 9.4×-3.2× | 5.9×-26.4× | 2.7×-26.2× | 0.5×-57.2× | |
| Earnings yield | -8.8%-22.8pp | -0.4%+14.9pp | 3.2%+18.5pp | 8.4%+24.9pp | 14%+31.4pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Stoke Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Stoke Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
